Related Experiment Video

Updated: Jun 22, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy

N Kumarasamy1, Vidya Madhavan, Kartik K Venkatesh

  • 1YRG Centre for AIDS Research and Education, VHS, Chennai, India. kumarasamy@yrgcare.org

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|June 16, 2009
PubMed

Insights

Continued use of failing antiretroviral therapy causes drug resistance mutations in HIV patients. This limits future treatment options and highlights the need for viral load monitoring in India.

Area of Science:

  • Virology
  • Infectious Diseases
  • Public Health

Background:

  • Highly active antiretroviral therapy (HAART) is crucial for managing human immunodeficiency virus (HIV) infection.
  • Treatment failure can arise from non-adherence or drug resistance, leading to accumulation of viral mutations.
  • Limited treatment options for second-line therapy necessitate understanding resistance patterns.

Purpose of the Study:

  • To investigate the prevalence and patterns of drug resistance mutations in Indian HIV patients experiencing first-line HAART failure.
  • To assess the impact of treatment failure on subsequent therapeutic choices.

Main Methods:

  • Retrospective analysis of 138 HIV-infected Indian patients.
  • Genotypic resistance testing to identify mutations in reverse transcriptase.
  • Evaluation of treatment history and immunologic response.

Main Results:

  • A high frequency of drug resistance mutations was observed in patients with treatment failure.
  • Specific mutation patterns were identified, potentially impacting second-line HAART efficacy.
  • Immunologic failure correlated significantly with the presence of resistance mutations.

Conclusions:

  • First-line HAART failure in Indian HIV patients is associated with a high burden of drug resistance mutations.
  • Understanding these resistance patterns is essential for optimizing HIV treatment strategies.
  • Routine viral load monitoring is recommended to detect treatment failure early and guide therapy adjustments.

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Viral Mutations00:36

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material for adaptive...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...